Biomarkers in inflammatory bowel diseases: Current status and proteomics identification strategies
Biomarkers in inflammatory bowel diseases: Current status and proteomics identification strategies
复制标题
DOI：
10.3748/wjg.v20.i12.3231
复制
发表时间：
2014-03-28
影响因子：
4.3
通讯作者：
Andersen, Vibeke
中科院分区：
文献类型：
--
作者：
Bennike, Tue;Birkelund, Svend;Andersen, Vibeke
炎症性肠病（IBD）的两种主要形式：溃疡性结肠炎（UC）和克罗恩病（CD）的非抗生素诊断代表了疾病早期阶段的挑战。诊断可以在症状出现后几年确定。因此，早期和准确诊断的蛋白质生物标志物可以帮助临床医生改善个体患者的治疗。此外，生物标志物可以帮助医生预测疾病进程，并以这种方式识别需要强化治疗的患者。疾病发作风险低的患者可避免使用伴随不良事件风险的药物治疗。此外，疾病和病程特异性生物标志物谱的鉴定可用于鉴定疾病发展和治疗中涉及的生物途径。了解疾病的一般机制，可以改善未来的预防和治疗策略的发展。因此，一组生物标志物的临床应用代表了具有潜在巨大价值的诊断和预后工具。近年来蛋白质组学研究（完整蛋白质含量的测定和定量）的技术发展使得发现新的生物标志物变得可行。几种IBD相关蛋白质生物标志物是已知的，但没有一种在日常使用中成功地用于区分CD和UC患者。肠道组织仍然是寻找新生物标志物的明显场所，随后可以对血液、尿液或粪便进行筛查。当考虑到肠道活检样品中遇到的蛋白质复杂性和质谱驱动的定量蛋白质组学领域的最新发展时，今天可以进行比以往任何时候都更彻底和准确的生物标志物发现奋进。在这篇综述中，我们报告了蛋白质组学IBD生物标志物的现状，并讨论了各种新兴的蛋白质组学策略，用于识别和表征新的生物标志物，以及建议未来的分析目标。(c)2014百世登出版集团有限公司有限公司All rights reserved.
Unambiguous diagnosis of the two main forms of inflammatory bowel diseases (IBD): Ulcerative colitis (UC) and Crohn's disease (CD), represents a challenge in the early stages of the diseases. The diagnosis may be established several years after the debut of symptoms. Hence, protein biomarkers for early and accurate diagnostic could help clinicians improve treatment of the individual patients. Moreover, the biomarkers could aid physicians to predict disease courses and in this way, identify patients in need of intensive treatment. Patients with low risk of disease flares may avoid treatment with medications with the concomitant risk of adverse events. In addition, identification of disease and course specific biomarker profiles can be used to identify biological pathways involved in the disease development and treatment. Knowledge of disease mechanisms in general can lead to improved future development of preventive and treatment strategies. Thus, the clinical use of a panel of biomarkers represents a diagnostic and prognostic tool of potentially great value. The technological development in recent years within proteomic research (determination and quantification of the complete protein content) has made the discovery of novel biomarkers feasible. Several IBD-associated protein biomarkers are known, but none have been successfully implemented in daily use to distinguish CD and UC patients. The intestinal tissue remains an obvious place to search for novel biomarkers, which blood, urine or stool later can be screened for. When considering the protein complexity encountered in intestinal biopsy-samples and the recent development within the field of mass spectrometry driven quantitative proteomics, a more thorough and accurate biomarker discovery endeavor could today be performed than ever before. In this review, we report the current status of the proteomics IBD biomarkers and discuss various emerging proteomic strategies for identifying and characterizing novel biomarkers, as well as suggesting future targets for analysis. (c) 2014 Baishideng Publishing Group Co., Limited. All rights reserved.